D.Western Therapeutics Institute AI Stock Analysis
Want to see JP:4576 full AI Analyst Report?
D.Western Therapeutics Institute (4576) AI Stock Analysis
D.Western Therapeutics Institute
(TSE/TYO:4576)
The score is held down primarily by weak financial performance: the company remains deeply unprofitable with declining revenue and continued negative free cash flow, requiring ongoing external financing. Technicals compound the concern, with the stock trading below all major moving averages and negative MACD momentum, although extremely oversold RSI and Stochastic readings suggest the selling may be stretched. Valuation offers little support given negative earnings and no dividend. Offsetting positives include a materially stronger balance sheet, lower leverage at 0.42x debt-to-equity, high gross margins, and a meaningful halving of losses and cash burn versus 2024, which keeps the recovery case alive for risk-tolerant investors.
D.Western Therapeutics Institute (4576) vs. iShares MSCI Japan ETF (EWJ)
- Market Cap
- JPY 2.76B
- Dividend Yield
- ―
- Average Volume (3M)
- 352.70K
- Price to Earnings (P/E)
- -4.1
- Beta (1Y)
- 0.03
- Revenue Growth
- -66.17%
- EPS Growth
- 54.10%
- Country
- Japan
- Employees
- 19
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
D.Western Therapeutics Institute Business Overview & Revenue Model
Company Description
D. Western Therapeutics Institute, Inc. is a biotechnology enterprise focused on the research, discovery, and innovation of various pharmaceutical drugs. The company's current portfolio includes GLANATEC and GLA-ALPHA, ophthalmic solutions prescribed...
D.Western Therapeutics Institute Financial Statement Overview
Summary
Financials reflect a development-stage biotech with deep unprofitability. The income statement (score 25) shows a ¥632 million net loss and a 7.9% revenue decline to ¥388 million, though losses halved versus 2024 and gross margin remains high at ~78%. Cash flow (score 28) is the weakest link, with ¥494 million of operating cash outflow and negative ¥497 million free cash flow, leaving the company reliant on external financing. The balance sheet (score 52) is the relative bright spot: equity nearly doubled to ¥1.44 billion and debt-to-equity improved to 0.42x from 1.09x. Overall, the improving loss and burn trajectory is encouraging, but there is no visible path to breakeven.
Income Statement
25NegativeBalance Sheet
52NeutralCash Flow
28Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 305.74M | 387.62M | 471.58M | 428.36M | 448.10M | 414.42M |
| Gross Profit | 251.40M | 301.24M | 424.74M | 391.70M | 420.53M | 394.32M |
| EBITDA | -611.09M | -572.35M | -1.23B | -775.59M | -390.75M | -110.03M |
| Net Income | -651.85M | -632.09M | -1.29B | -812.41M | -429.69M | -149.00M |
Balance Sheet | ||||||
| Total Assets | 1.97B | 2.17B | 1.67B | 2.37B | 2.96B | 2.46B |
| Cash, Cash Equivalents and Short-Term Investments | 1.54B | 1.71B | 1.13B | 1.87B | 2.33B | 1.93B |
| Total Debt | 594.17M | 605.18M | 797.98M | 885.12M | 967.69M | 340.00M |
| Total Liabilities | 654.26M | 734.01M | 935.57M | 1.09B | 1.08B | 427.72M |
| Stockholders Equity | 1.31B | 1.44B | 733.87M | 1.28B | 1.86B | 2.01B |
Cash Flow | ||||||
| Free Cash Flow | 0 | -496.54M | -1.31B | -601.76M | -364.58M | -179.21M |
| Operating Cash Flow | 0 | -493.79M | -1.30B | -586.82M | -354.77M | -176.31M |
| Investing Cash Flow | 0 | -2.45M | -10.01M | -15.25M | -139.89M | -111.15M |
| Financing Cash Flow | 0 | 1.08B | 567.63M | 134.47M | 867.30M | -104.46M |
D.Western Therapeutics Institute Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4576, the sentiment is Negative. The current price of 47.00 is below the 20-day moving average (MA) of 55.60, below the 50-day MA of 67.22, and below the 200-day MA of 82.05, indicating a bearish trend. The MACD of -5.89 indicates Positive momentum. The RSI at 21.42 is Positive, neither overbought nor oversold. The STOCH value of 18.61 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:4576.
D.Western Therapeutics Institute Peers Comparison
Overall Rating
JP:497842Neutral
JP:459239Underperform
JP:457638Underperform
JP:459938Underperform
JP:459337Underperform
JP:777637Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 42Neutral | JPY 11.33B | -23.68 | ― | ― | -8.23% | -48.10% | |
| 39Underperform | JPY 63.07B | -16.39 | -37.79% | ― | ― | 5.71% | |
| 38Underperform | JPY 2.76B | -4.06 | -47.54% | ― | -66.17% | 54.10% | |
| 38Underperform | JPY 7.90B | -4.21 | ― | ― | ― | 4.85% | |
| 37Underperform | JPY 27.92B | -12.37 | ― | ― | -51.55% | 52.19% | |
| 37Underperform | JPY 6.11B | -4.70 | ― | ― | -49.43% | -3.77% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| JP:4576 | D.Western Therapeutics Institute, Inc. | 47.00 | -50.00 | -51.55% | |
| JP:4592 | SanBio Co | 808.00 | -1533.00 | -65.48% | |
| JP:4593 | Healios KK | 206.00 | -280.00 | -57.61% | |
| JP:4599 | StemRIM Inc. | 126.00 | -151.00 | -54.51% | |
| JP:4978 | ReproCELL Inc. | 105.00 | -55.00 | -34.38% | |
| JP:7776 | CellSeed Inc. | 154.00 | -225.00 | -59.37% |
D.Western Therapeutics Institute Corporate Events
D. Western Therapeutics Outlines Q2 FY12/26 Results and Outlook
D. Western Therapeutics Institute has released briefing materials for its second quarter results for the fiscal year ending December 2026. The documents outline financial performance, progress in business activities, and an updated forecast for the f...
D.Western Therapeutics Posts Deeper Losses, Keeps 2026 Outlook Unchanged
D.Western Therapeutics Institute reported consolidated net sales of ¥33 million for the first half of 2026, an 80.9% year-on-year decline, with an operating loss of ¥312 million and a net loss attributable to owners of the parent of ¥323 million. Des...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 06, 2026
